{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:21:57Z","timestamp":1785432117523,"version":"3.56.0"},"reference-count":49,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Multiple sclerosis (MS) is a neurodegenerative central nervous system disorder causing axonal damage and disability. Relapses develop over hours or days and then subside over weeks. Disease-modifying drugs (DMDs) influence disease activity. Interferon beta-1A (IFN-b-1A) is a widely used first-line treatment for relapsing remitting MS (RRMS) that reduces central nervous system inflammation. Fingolimod affects lymphocyte trafficking. B-cell therapy (rituximab) depletes circulating CD20+ B cells in cerebrospinal fluid, but their specific effects in RRMS remain limited.\nObjective:\u00a0The aim of the present study was to evaluate the effect of DMDs such as IFN-b-1A, fingolimod and rituximab on neurofilament light chain (NFL) and chitinase 3-like 1 (CHI3L1) serum levels, and some biomarkers of plasmacytoid dendritic cells (pDCs) in RRMS patients.\nMethods:\u00a0Thirty healthy controls and 44 RRMS patients actively receiving their DMDs, were recruited into this study. Patients were divided into three groups according to DMDs type: Group 1 (n\u00a0= 17) received IFN-b-1A, Group 2 (n\u00a0= 20) received fingolimod, and Group 3 (n\u00a0= 7) received rituximab. Patients of all ages and both sexes were included.\nResults:\u00a0Serum NFL (84.1% sensitivity and 60.0% specificity) and CHI3L1 (90.9% sensitivity and 73.0% specificity) levels were higher in patients than in controls (p\u00a0\u2264 0.001), with higher levels of NFL in the B-cell therapy group compared with IFN-b-1A (p\u00a0\u2264 0.001) and fingolimod (p\u00a0= 0.005), and higher levels of CHI3L1 in the B-cell group compared to IFN-b-1A (p\u00a0= 0.001) and fingolimod (p\u00a0= 0.015). Plasmacytoid dendritic cells showed no difference in tolerogenic and migratory function between the DMDs groups.\nConclusion:\u00a0Disease-modifying drug type (IFN-b-1A, fingolimod, and B-cell therapy) impacts NFL and CHI3L1 serum levels as drug response biomarkers and relates to clinical data of MS patients, but has no diverse impact on the migratory and tolerogenic function of pDCs.\nWhat this study adds:\u00a0The serum NFL and CHI3L1 need to be validated as drug response biomarkers in RRMS patients, evaluating the DMDs\u2019 effect on immunocellular level by studying migratory and tolerogenic functions of pDCs.<\/jats:p>","DOI":"10.4102\/ajlm.v15i1.2901","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:50:38Z","timestamp":1768895438000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis"],"prefix":"10.4102","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6917-7224","authenticated-orcid":false,"given":"Dalia T.","family":"Kamal","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jaj8n65","id-type":"ROR","asserted-by":"publisher"}],"name":"Assiut University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-3263","authenticated-orcid":false,"given":"Sohair K.","family":"Sayed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jaj8n65","id-type":"ROR","asserted-by":"publisher"}],"name":"Assiut University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0198-8764","authenticated-orcid":false,"given":"Tarek A.","family":"Rageh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jaj8n65","id-type":"ROR","asserted-by":"publisher"}],"name":"Assiut University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7800-4732","authenticated-orcid":false,"given":"Basant","family":"Rashad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jaj8n65","id-type":"ROR","asserted-by":"publisher"}],"name":"Assiut University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-7095","authenticated-orcid":false,"given":"Eman R.","family":"Badawy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jaj8n65","id-type":"ROR","asserted-by":"publisher"}],"name":"Assiut University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances. Lancet Neurol. 2021;20:470\u2013483. https:\/\/doi.org\/10.1016\/S1474-4422(21)00063-6","DOI":"10.1016\/S1474-4422(21)00063-6"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sospedra, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683\u2013747. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115707","DOI":"10.1146\/annurev.immunol.23.021704.115707"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis \u2013 A review. Eur J Neurol. 2019;26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819","DOI":"10.1111\/ene.13819"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dighriri IM, Aldalbahi AA, Albeladi F, et al. An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis. Cureus. 2023;15(1):e33242. https:\/\/doi.org\/10.7759\/cureus.33242","DOI":"10.7759\/cureus.33242"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Amr H, Islam A, Mohamed H. Multiple sclerosis in Middle East North Africa (MENA) region: Challenges, achievements and opportunities. Mult Scler Relat Disord. 2023;71:104264. https:\/\/doi.org\/10.1016\/j.msard.2022.104264","DOI":"10.1016\/j.msard.2022.104264"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Yamout BI, Assaad W, Tamim H, Mrabet S, Goueider R. Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region. Mult Scler J Exp Transl Clin. 2020;6(1):2055217319841881. https:\/\/doi.org\/10.1177\/2055217319841881","DOI":"10.1177\/2055217319841881"},{"key":"ref6","unstructured":"Hashem S, El-Tamawy MS, Hamdy S, Elmasry T. Epidemiology of multiple sclerosis in Egypt. Egypt J Neurol Psychiat Neurosurg. 2010;47(4):625\u2013632."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med. 2020;20(4):380\u2013383. https:\/\/doi.org\/10.7861\/clinmed.2020-0292","DOI":"10.7861\/clinmed.2020-0292"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Marastoni D, Foschi M, Eccher C, et al. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis. Front Immunol. 2024;15:1343892. https:\/\/doi.org\/10.3389\/fimmu.2024.1343892","DOI":"10.3389\/fimmu.2024.1343892"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ferreira-Atuesta C, Reyes S, Giovanonni G, Gnanapavan S. The evolution of neurofilament light chain in multiple sclerosis. Front Neurosci. 2021;15:642384. https:\/\/doi.org\/10.3389\/fnins.2021.642384","DOI":"10.3389\/fnins.2021.642384"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kusnierova P, Revendova KZ, Karasova K, et al. Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis. Mult Scler Relat Disord. 2024;91:105915. https:\/\/doi.org\/10.1016\/j.msard.2024.105915","DOI":"10.1016\/j.msard.2024.105915"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Piacente F, Bottero M, Benzi A, et al. Neuroprotective potential of dendritic cells and sirtuins in multiple sclerosis. Int J Mol Sci. 2022;23:4352. https:\/\/doi.org\/10.3390\/ijms23084352","DOI":"10.3390\/ijms23084352"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dr\u00e9nou B, Amiot L, Setterblad N, et al. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. J Leukoc Biol. 2005;77(4):560\u2013567. https:\/\/doi.org\/10.1189\/jlb.0704423","DOI":"10.1189\/jlb.0704423"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Passeri L, Marta F, Bassi V, Gregori S. Tolerogenic dendritic cell-based approaches in autoimmunity. Int J Mol Sci. 2021;22:8415. https:\/\/doi.org\/10.3390\/ijms22168415","DOI":"10.3390\/ijms22168415"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Morante-Palacios O, Fondelli F, Ballestar E, Mart\u00ednez-C\u00e1ceres EM. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol. 2021;42(1):59\u201375. https:\/\/doi.org\/10.1016\/j.it.2020.11.001","DOI":"10.1016\/j.it.2020.11.001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Moraes AS, Boldrini VO, Dionete AC, et al. Decreased neurofilament L chain levels in cerebrospinal fluid and tolerogenic plasmacytoid dendritic cells in natalizumab-treated multiple sclerosis patients \u2013 Brief research report. Front Cell Neurosci. 2021;15:705618. https:\/\/doi.org\/10.3389\/fncel.2021.705618","DOI":"10.3389\/fncel.2021.705618"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Liu C, Zhu J, Mi Y, Jin T. Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis. J Neuroinflamm. 2022;19:298. https:\/\/doi.org\/10.1186\/s12974-022-02663-z","DOI":"10.1186\/s12974-022-02663-z"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy. Neurology. 2010;74(suppl 1):S62\u2013S69. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c980fb","DOI":"10.1212\/WNL.0b013e3181c980fb"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cohan SL, Hendin BA, Reder AT, et al. Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS Drugs. 2021;35(7):743\u2013767. https:\/\/doi.org\/10.1007\/s40263-021-00822-z","DOI":"10.1007\/s40263-021-00822-z"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Singer BA. Initiating oral fingolimod treatment in patients with multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):269\u2013275. https:\/\/doi.org\/10.1177\/1756285613491520","DOI":"10.1177\/1756285613491520"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: A review. J Neurol. 2022;269(1):159\u2013183. https:\/\/doi.org\/10.1007\/s00415-020-10362-z","DOI":"10.1007\/s00415-020-10362-z"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175\u2013191. https:\/\/doi.org\/10.3758\/BF03193146","DOI":"10.3758\/BF03193146"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Madill E, Moreira Ferreira V, Healy B, et al. Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis. Mult Scler. 2025;31(8):944\u2013954. https:\/\/doi.org\/10.1177\/13524585251335521","DOI":"10.1177\/13524585251335521"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Norgren N, Karlsson JE, Rosengren L, Stigbrand T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 2002;21(1):53\u201359. https:\/\/doi.org\/10.1089\/15368590252917647","DOI":"10.1089\/15368590252917647"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A. 2006;69(9):1037\u20131042. https:\/\/doi.org\/10.1002\/cyto.a.20333","DOI":"10.1002\/cyto.a.20333"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Peterson JW, B\u00f6 L, M\u00f6rk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389\u2013400. https:\/\/doi.org\/10.1002\/ana.1123","DOI":"10.1002\/ana.1123"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. J Am Med Assoc. 2019;321:175\u2013187. https:\/\/doi.org\/10.1001\/jama.2018.20588","DOI":"10.1001\/jama.2018.20588"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Amato MP, Fonderico M, Portaccio E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143:3013\u20133024. https:\/\/doi.org\/10.1093\/brain\/awaa251","DOI":"10.1093\/brain\/awaa251"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Cobo-Calvo A, Tur C, Otero-Romero S, et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology. 2023;101:e1280\u2013e1292. https:\/\/doi.org\/10.1212\/WNL.0000000000207664","DOI":"10.1212\/WNL.0000000000207664"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113\u2013126. https:\/\/doi.org\/10.1016\/S1474-4422(13)70233-3","DOI":"10.1016\/S1474-4422(13)70233-3"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","DOI":"10.1038\/s41582-018-0058-z"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gil-Perotin S, Castillo-Villalba J, Cubas-Nu\u00f1ez L, et al. Combined cerebrospinal fluid neurofilament light chain protein and Chitinase-3 like-1 levels in defining disease course and prognosis in multiple sclerosis. Front Neurol. 2019;10:1008\u20131008. https:\/\/doi.org\/10.3389\/fneur.2019.01008","DOI":"10.3389\/fneur.2019.01008"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler J. 2016;23:62\u201371. https:\/\/doi.org\/10.1177\/1352458516639384","DOI":"10.1177\/1352458516639384"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zakaria M, Zamzam DA, Abdel Hafeez MA, et al. Clinical characteristics of patients with multiple sclerosis enrolled in a new registry in Egypt. Mult Scler Relat Disord. 2016;10:30\u201335. https:\/\/doi.org\/10.1016\/j.msard.2016.06.013","DOI":"10.1016\/j.msard.2016.06.013"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Macaron G, Larochelle C, Arbour N, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol. 2023;14:1197212. https:\/\/doi.org\/10.3389\/fneur.2023.1197212","DOI":"10.3389\/fneur.2023.1197212"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kavaliunas A, Stawiarz L, Hedbom J, Glaser A, Hillert J. The influence of immunomodulatory treatment on the clinical course of multiple sclerosis. Adv Exp Med Biol. 2014;822:19\u201324.","DOI":"10.1007\/978-3-319-08927-0_5"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u20131136. https:\/\/doi.org\/10.1177\/1352458517694432","DOI":"10.1177\/1352458517694432"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"R\u00edo J, Castill\u00f3 J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon \u03b2 in MS. Mult Scler J. 2009;15:848\u2013853. https:\/\/doi.org\/10.1177\/1352458509104591","DOI":"10.1177\/1352458509104591"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005;4:32\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(04)00964-0","DOI":"10.1016\/S1474-4422(04)00964-0"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmestr\u00f6m C. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol. 2016;292:52\u201357. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.013","DOI":"10.1016\/j.jneuroim.2016.01.013"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Ma\u00f1\u00e9-Mart\u00ednez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol. 2016;299:112\u2013117. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.08.004","DOI":"10.1016\/j.jneuroim.2016.08.004"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141:2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","DOI":"10.1093\/brain\/awy154"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Bittner S, Steffen F, Uphaus T, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. eBioMedicine. 56:102807. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102807","DOI":"10.1016\/j.ebiom.2020.102807"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","DOI":"10.1002\/ana.24954"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Calabresi PA, Arnold DL, Sangurdekar D, et al. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Mult Scler. 2021;27:1497\u20131505. https:\/\/doi.org\/10.1177\/1352458520972573","DOI":"10.1177\/1352458520972573"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Thebault S, Reaume M, Marrie RA, et al. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022;59:103535. https:\/\/doi.org\/10.1016\/j.msard.2022.103535","DOI":"10.1016\/j.msard.2022.103535"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Floro S, Carandini T, Pietroboni AM, De Riz MA, Scarpini E, Galimberti D. Role of Chitinase 3-like 1 as a biomarker in multiple sclerosis: A systematic review and meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1164. https:\/\/doi.org\/10.1212\/NXI.0000000000001164","DOI":"10.1212\/NXI.0000000000001164"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Von Glehn F, Santos LM, Balashov KE. Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. Immunotherapy. 2012;4:1053\u20131061. https:\/\/doi.org\/10.2217\/imt.12.117","DOI":"10.2217\/imt.12.117"}],"container-title":["African Journal of Laboratory Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:50:45Z","timestamp":1768895445000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/2901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/ajlm.v15i1.2901","relation":{},"ISSN":["2225-2002","2225-2010"],"issn-type":[{"value":"2225-2002","type":"print"},{"value":"2225-2010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"a2901"}}